Recombinant erythropoietin
“Epoetin Alfa BS Inj. JCR”
“Epoetin Alfa BS Inj. JCR” was launched in May 2010 as the first made-in-Japan biosimilar. This product is for the treatment of anemia, a common indication in dialysis patients.
The product leverages a series of JCR biotechnologies, and substantial clinical trials were conducted during its development phase.
・Renal Anemia in dialysis patients*
・Anemia of prematurity
*Renal Anemia in dialysis patients: anemia is caused primarily by reduced synthesis of a hematopoietic factor called erythropoietin due to renal disorder, it is a complication often observed in chronic dialysis patients.